Syros Pharmaceuticals, Inc. SYRS
We take great care to ensure that the data presented and summarized in this overview for Syros Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SYRS
Top Purchases
Top Sells
About SYRS
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at SYRS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 03
2024
|
David Roth Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,451
-100.0%
|
$41,804
$4.95 P/Share
|
|
Apr 02
2024
|
David Roth Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
150
-1.42%
|
$600
$4.98 P/Share
|
|
Apr 01
2024
|
Nancy A Simonian |
SELL
Payment of exercise price or tax liability
|
Direct |
14,052
-9.64%
|
$70,260
$5.12 P/Share
|
|
Apr 01
2024
|
Kristin Stephens Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,218
-14.32%
|
$21,090
$5.12 P/Share
|
|
Apr 01
2024
|
Jason Haas Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,732
-16.16%
|
$23,660
$5.12 P/Share
|
|
Apr 01
2024
|
David Roth Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,732
-30.86%
|
$23,660
$5.12 P/Share
|
|
Apr 01
2024
|
Conley Chee President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,500
-13.46%
|
$17,500
$5.12 P/Share
|
|
Mar 31
2024
|
Nancy A Simonian |
BUY
Exercise of conversion of derivative security
|
Direct |
45,566
+13.35%
|
-
|
|
Mar 31
2024
|
Kristin Stephens Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,666
+19.24%
|
-
|
|
Mar 31
2024
|
Jason Haas Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,333
+21.21%
|
-
|
|
Mar 31
2024
|
David Roth Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,333
+48.26%
|
-
|
|
Mar 31
2024
|
Conley Chee President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,666
+21.61%
|
-
|
|
Mar 28
2024
|
Gerald E Quirk Chief Legal & Compliance Offic |
SELL
Payment of exercise price or tax liability
|
Direct |
7,046
-15.05%
|
$35,230
$5.59 P/Share
|
|
Mar 27
2024
|
Gerald E Quirk Chief Legal & Compliance Offic |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+32.47%
|
-
|
|
Dec 21
2023
|
Srinivas Akkaraju Director |
BUY
Open market or private purchase
|
Indirect |
904,977
+33.62%
|
$3,619,908
$4.42 P/Share
|
|
Dec 12
2023
|
David Roth Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,287
-100.0%
|
$25,148
$4.95 P/Share
|
|
Dec 06
2023
|
David Roth Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,287
-50.0%
|
$18,861
$3.95 P/Share
|
|
Nov 01
2023
|
Conley Chee President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,004
-32.73%
|
$12,008
$2.22 P/Share
|
|
Nov 01
2023
|
Kristin Stephens Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,676
-26.44%
|
$11,352
$2.22 P/Share
|
|
Nov 01
2023
|
David Roth Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,301
-33.38%
|
$12,602
$2.22 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 268K shares |
|---|---|
| Grant, award, or other acquisition | 24K shares |
| Open market or private purchase | 905K shares |
| Payment of exercise price or tax liability | 82.9K shares |
|---|---|
| Open market or private sale | 31.2K shares |